Thota PN, et al. - In this single-center study, authors studied 264 individuals to evaluate the outcomes of endoscopic eradication therapy (EET) in subjects with Barrett’s esophagus (BE) with visible lesions (VLs) vs BE cases with flat dysplasia. They noticed longer segments of BE (5 vs 4 cm) and greater prevalence of high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) (63.6% vs 29.4%) among subjects with VL when compared with flat dysplasia cases. They also reported lesser incident lesions harboring in HGD/EAC vs prevalent lesions (28.1% vs 61.8%). No significant differences in the eradication of metaplasia/dysplasia between the groups were observed. They concluded the development of VL during EET in approximately 19% of BE patients.